"contracts with 5 high complexity CLIA labs that we anticipate will generate over $36.5 million dollars in revenue for Todos over the next 8 months. Each one of these clients has informed us that the demand for testing has increased substantially since those contracts were entered into and we are now preparing to support larger demand for our products from those clients"

No, don't pull the trigger on uplisting. Stay on the OTC cause that's where real investors are.
All real institutions know where the true companies are, right here on the OTC.

The talk of no RS is brainless and in fact irresponsible.

Get the dilution to cease, see where the stock price goes and then pull the trigger to uplist ASAP if possible.

It will be very difficult to convince governments to do business with an OTC company.
Get to the NASDAQ and institutional investors, government bodies and news outlets will take Todos and what they are building far more seriously.

There's a story to be told with TODOS and it's being lost spent on the OTC.

It's a budding diagnostic company that has a lot in the pipeline and happening near term.

Aloha